Skip to main content

Genovac Antibody Discovery Launches in NDSU Research and Technology Park

Written by Customer Service on . Posted in Mergers And Acquisitions.

Fargo, North Dakota, April 26, 2021 (GLOBE NEWSWIRE) —

Genovac Antibody Discovery has launched in the United States following a management buyout of an antibody discovery business unit owned by Aldevron, a U.S.-based contract manufacturing organization. The unit, which was established and operates in Freiburg, Germany, is now headquartered in Fargo, N.D.

Brian Walters, who had been serving as the president of Aldevron’s Antibody Discovery Group, led the management buyout and is now Genovac’s president and CEO.

Genovac is a contract research organization that discovers and develops antibodies for therapeutic, diagnostic and research and development market segments, with clients in North America, Europe, Australia and Asia. The company’s core technology, genetic immunization, enables rapid antibody discovery against biopharma’s most challenging targets.

The company has served the biopharmaceutical industry for more than 20 years and has completed over 3,500 projects, providing antibodies that have been developed into clinical and commercial drugs. Genovac also has completed more than 25 client and internal COVID-19 campaigns, and has developed two antibodies that successfully neutralize the United Kingdom, Brazilian and South African mutations.

In addition to genetic immunization, Genovac has acquired the most advanced single-cell screening technology in the world, the Beacon® Optofluidic System developed by Berkeley Lights. The platform enables Genovac to make DNA for genetic immunization in one week, compared to the months it would take using the traditional, protein-based method for antibody discovery. By combining its expertise in genetic immunization with advanced, one-day, single-cell screening technology, Genovac is able to generate antibodies rapidly, a critical element to developing drugs to treat infectious diseases such as the coronavirus and its mutations.

Genovac also was the first Beacon system user in the world to successfully screen wild type and transgenic rat cells, and the company is currently aiming to be the first to screen rabbit and alpaca cells. All are rich sources for antibodies that can be developed into human therapeutics.

Walters was Aldevron’s chief financial officer prior to leading its Antibody Discovery Group. Before that he held multiple leadership positions in economic development organizations across the United States.

For more information visit our website. 

– 30 –

Attachment

  • Brian Walters

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.